Baxter is a global medical-products company supplying devices and hospital consumables used in surgery, critical care and outpatient settings, a category tied to stable procedural volumes and recurring hospital demand. The stock sits in the Medical Devices & Surgical Robotics theme, where durability of sales and incremental product adoption matter for leadership.
Revenue has grown at mid-single-digit year-over-year rates across recent quarters, rising from $2.49 billion in CY2024 Q1 to $2.96 billion in CY2026 Q2. Revenue acceleration is not present, but GAAP diluted EPS has shown improvement and less volatility recently; GAAP diluted EPS turned positive in several quarters and was $0.24 in CY2026 Q2, a year-over-year increase of about 33%. The company has had intermittent negative GAAP quarters in the past, which illustrates earnings volatility even as top-line trends remain steady.
Technically, the breakout above a 168-session base on 2026-07-28 is the clearest near-term driver. The base recorded constructive demand at roughly 2.72x its prior 30-day average during the final 63 sessions, and the stock reclaimed its 200-day moving average on 2026-06-23. Institutional ownership is broad, with 956 reporting institutions and roughly 1.10% of shares held, and the issue passed seven of seven trend checks, which supports a leadership case within the medical-devices theme.
Why now
The breakout is recent and validated: price cleared a 168-session base on 2026-07-28 after demand surged to about 2.7x prior levels, and the stock reclaimed its 200-day average on 2026-06-23; that technical shift coincides with a CY2026 Q2 report (10-Q filed 2026-07-30) showing $2.96 billion in revenue, up about 5.34% year-over-year, and GAAP diluted EPS of $0.24, improving year-over-year, which together create a near-term convergence of fundamental and technical momentum.
The setup
Last close was $25.70 (2026-09-02), above the 50-day SMA ($24.42) and 200-day SMA ($20.23) but slightly below the 9- and 21-day EMAs (26.04 and 25.96). The breakout from the base is valid but price is no longer inside the initial pivot band (pivot 23.71, initial entry range 23.24–24.90), with the setup recorded 25 sessions ago. RSI is neutral at 49.9, the stock sits within about 9.4% of its 52-week high, and volume measures show accumulation, with a 30-day setup demand ratio near 2.72 and a 50-day up/down volume ratio of 1.48.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (12 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $2.05 (-10%) · FY'27E $2.04 (-1%) — 12 analysts
Risks
Revenue growth is steady but not accelerating, raising the risk that top-line momentum could stall. GAAP diluted EPS has been volatile, including negative quarters, so earnings swings or one-time items could produce adverse surprises. The breakout is already outside the initial entry zone and has been in place for multiple weeks, which raises the risk of a short-term pullback if recent demand does not continue.
Framework fit
CANSLIM
6/7- CCurrent quarterly GAAP EPS growth ≥ 25%+33%✓
- AAnnual GAAP EPS growth ≥ 25%insufficient data—
- NNew highs — within 15% of 52-week high-9.35%✓
- SSupply/demand — up-day volume leads1.48x✓
- LLeader — outperforming the S&P 500+23% 6m✓
- IInstitutional sponsorshipmodel score 8/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Broke above a 168-session base on 2026-07-28. Breakout volume was 1.17x its prior 30-day average. Strongest qualifying base demand was 2.72x on 2026-04-30.